OPKO Health (NASDAQ:OPK) Lowered to Sell Rating by StockNews.com

StockNews.com lowered shares of OPKO Health (NASDAQ:OPK) from a hold rating to a sell rating in a report published on Wednesday morning.

OPK has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, January 8th. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th.

OPKO Health Stock Performance

OPKO Health stock opened at $1.47 on Wednesday. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.76. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market cap of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.63. The firm’s fifty day moving average price is $1.54 and its 200-day moving average price is $1.50.

Insider Buying and Selling

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average cost of $1.48 per share, with a total value of $740,000.00. Following the completion of the purchase, the chief executive officer now directly owns 213,036,477 shares of the company’s stock, valued at $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have bought a total of 1,804,255 shares of company stock valued at $2,764,605 over the last three months. 47.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Several institutional investors and hedge funds have recently bought and sold shares of OPK. World Investment Advisors LLC bought a new position in shares of OPKO Health during the third quarter valued at approximately $61,000. Virtu Financial LLC bought a new position in OPKO Health in the 3rd quarter worth $120,000. Barclays PLC lifted its position in shares of OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares during the period. Orion Portfolio Solutions LLC bought a new stake in shares of OPKO Health during the 3rd quarter valued at about $45,000. Finally, XTX Topco Ltd increased its position in shares of OPKO Health by 166.5% during the third quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 67,883 shares during the period. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.